JPH11509081A - 新規の複製プロセス - Google Patents
新規の複製プロセスInfo
- Publication number
- JPH11509081A JPH11509081A JP8516287A JP51628796A JPH11509081A JP H11509081 A JPH11509081 A JP H11509081A JP 8516287 A JP8516287 A JP 8516287A JP 51628796 A JP51628796 A JP 51628796A JP H11509081 A JPH11509081 A JP H11509081A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- vero
- trypsin
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Seasonings (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. Vero細胞培養物におけるヒトインフルエンザウイルスの複製のプロセスで あって、インフルエンザウイルスの増殖サイクルを通して、培養培地中に約0.05 μg/mlの最少濃度のトリプシンの存在下で、インフルエンザウイルスを使用して Vero細胞を感染させる工程を包含する、プロセス。 2. 前記Vero細胞を1細胞あたり約1×10-5TCID50と約1×10-6TCID50との間 の感染多重度でインフルエンザウイルスを使用して感染させる、請求項1に記載 のプロセス。 3. 前記感染多重度が1細胞あたり約1×10-5TCID50と約1×10-6TCID50との 間である、請求項1に記載のプロセス。 4. 前記トリプシンが0.05μg/mlよりも高いトリプシン濃度を維持するために 、Vero細胞複製の間、培養培地へ調節的に加えられる、請求項1に記載のプロセ ス。 5. 前記トリプシンの濃度が増殖サイクルを通して約0.05μg/mlと約0.5μg/m lとの間で維持される、請求項1に記載のプロセス。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34025494A | 1994-11-16 | 1994-11-16 | |
US08/340,254 | 1994-11-16 | ||
PCT/US1995/014814 WO1996015232A1 (en) | 1994-11-16 | 1995-11-13 | Novel replication process |
CA002205677A CA2205677A1 (en) | 1994-11-16 | 1997-05-16 | Novel replication process |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11509081A true JPH11509081A (ja) | 1999-08-17 |
Family
ID=25679347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8516287A Ceased JPH11509081A (ja) | 1994-11-16 | 1995-11-13 | 新規の複製プロセス |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0808361A4 (ja) |
JP (1) | JPH11509081A (ja) |
AU (1) | AU694592B2 (ja) |
NO (1) | NO972239L (ja) |
NZ (1) | NZ296861A (ja) |
WO (1) | WO1996015232A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007132763A1 (ja) | 2006-05-11 | 2007-11-22 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | インフルエンザウイルスの増殖方法 |
JP2010042030A (ja) | 2000-04-28 | 2010-02-25 | St Judes Children's Research Hospital | 感染性インフルエンザウイルスの発生のためのトランスフェクションシステム |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
DE19655440B4 (de) * | 1996-04-01 | 2013-09-05 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur Herstellung eines Influenzaimpfstoffs |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
US7790434B2 (en) | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
BRPI0612268A2 (pt) | 2005-06-21 | 2009-01-27 | Medimmune Vaccines Inc | Ácido nucleico isolado, vetor de expressço, mÉtodos para produzir um rna genâmico da influenza, para produzir um vÍrus da influenza recombinante, para gerar um vÍrus de rna segmentado de filamento negativo recombinante nas cÉlulas caninas cultivadas e para gerar partÍculas virais da influenza infecciosa em cÉlulas caninas cultivadas, cÉlula, e, vÍrus |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
AR080972A1 (es) | 2010-04-28 | 2012-05-23 | Abbott Biologicals Bv | Produccion de componentes virales |
CN102586195B (zh) * | 2011-12-01 | 2013-09-04 | 哈药集团生物疫苗有限公司 | 一种利用Vero传代细胞制备禽流感病毒及其灭活疫苗的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
CA1122527A (en) * | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
-
1995
- 1995-11-13 JP JP8516287A patent/JPH11509081A/ja not_active Ceased
- 1995-11-13 AU AU41589/96A patent/AU694592B2/en not_active Expired
- 1995-11-13 NZ NZ296861A patent/NZ296861A/en not_active IP Right Cessation
- 1995-11-13 WO PCT/US1995/014814 patent/WO1996015232A1/en not_active Application Discontinuation
- 1995-11-13 EP EP95939952A patent/EP0808361A4/en not_active Withdrawn
-
1997
- 1997-05-15 NO NO972239A patent/NO972239L/no not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010042030A (ja) | 2000-04-28 | 2010-02-25 | St Judes Children's Research Hospital | 感染性インフルエンザウイルスの発生のためのトランスフェクションシステム |
WO2007132763A1 (ja) | 2006-05-11 | 2007-11-22 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | インフルエンザウイルスの増殖方法 |
US7883844B2 (en) | 2006-05-11 | 2011-02-08 | Juridical Foundation The Chemosero-Therapeutic Research Institute | Method for propagating influenza virus |
Also Published As
Publication number | Publication date |
---|---|
NO972239D0 (no) | 1997-05-15 |
EP0808361A1 (en) | 1997-11-26 |
AU4158996A (en) | 1996-06-06 |
WO1996015232A1 (en) | 1996-05-23 |
EP0808361A4 (en) | 2001-07-18 |
NZ296861A (en) | 1998-05-27 |
NO972239L (no) | 1997-07-16 |
AU694592B2 (en) | 1998-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5824536A (en) | Influenza virus replicated in mammalian cell culture and vaccine production | |
Lazarowitz et al. | Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide | |
Kaverin et al. | Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity | |
EP0891420B1 (en) | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
JP4331432B2 (ja) | ワクチンの生成方法 | |
WO1997038094A9 (en) | Influenza virus replicated in mammalian cell culture and vaccine production | |
EP2022849A1 (en) | Method for proliferation of influenza virus | |
KR20050027164A (ko) | 세포 배양물에서 바이러스의 증식 방법 | |
JPH11509081A (ja) | 新規の複製プロセス | |
Basak et al. | Studies on the role of glycosylation in the functions and antigenic properties of influenza virus glycoproteins | |
CA2458543A1 (en) | Compositions and methods for treatment of cancer | |
AU2004249802B2 (en) | Improvements in virus production | |
CA2744354A1 (en) | Method for production of ph stable enveloped viruses | |
WO2020166524A1 (ja) | 増殖方法 | |
Slosaris et al. | Elevated virulence of Newcastle disease virus strains following serial passages in kidney cells in vitro | |
Choppin et al. | Genetics, Replication, and Inhibition of Replication of Influenza Virus: Summary of Influenza Workshop VII | |
CA2205410A1 (en) | Novel replication process | |
CA2205677A1 (en) | Novel replication process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040322 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040701 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040713 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040817 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20041122 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050104 |